[Antinuclear antibodies in patients with chronic fatigue syndrome].
Nishikai, Masahiko · Nihon rinsho. Japanese journal of clinical medicine · 2007
Quick Summary
This review examined whether people with ME/CFS have specific antibodies (immune proteins) that attack their own body cells. Researchers found that 15-25% of ME/CFS patients had these antibodies, but the patterns varied widely and were generally weak. A few new antibodies specific to ME/CFS were identified, with one type appearing in 13% of patients studied and linked to severe fatigue and concentration problems.
Why It Matters
Identifying disease-specific autoantibodies could help validate ME/CFS as a biological condition with measurable immune markers, potentially improving diagnosis and understanding disease mechanisms. These findings suggest that autoimmune processes may contribute to specific ME/CFS symptoms like severe fatigue and cognitive dysfunction.
Observed Findings
15-25% of ME/CFS patients showed positive ANA with indirect immunofluorescence on HEp-2 cells
ANA titers in positive patients were consistently low
Immunofluorescent staining patterns among ANA-positive patients were heterogeneous
Anti-68/48kD protein antibodies were detected in 13% of 114 ME/CFS patients versus 0% of healthy controls
ME/CFS patients with anti-68/48kD antibodies reported higher frequencies of hypersomnia and concentration difficulties
Inferred Conclusions
Certain autoantibodies may be specifically associated with ME/CFS rather than general immune activation
Autoimmune mechanisms may contribute to particular ME/CFS symptoms, particularly fatigue and cognitive impairment
Autoantibody patterns in ME/CFS differ from those in systemic lupus erythematosus and other connective tissue diseases, supporting differential diagnosis
Remaining Questions
Why do conflicting findings from different research groups persist, and what methodological differences explain the variation in reported ANA frequencies?
Are the identified autoantibodies functional drivers of ME/CFS symptoms or biomarkers of underlying pathology?
What This Study Does Not Prove
This review does not prove that ANA causes ME/CFS or that positive antibodies are necessary for diagnosis—correlation does not equal causation. The lack of confirmation by other research groups for some reported patterns suggests findings require independent validation before clinical application. The study also does not establish whether these antibodies are primary disease drivers or secondary effects of the illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →